|
|
阿帕替尼联合免疫检查点抑制剂治疗晚期胃肝样腺癌1例并文献复习
|
Abstract:
胃肝样腺癌是一种极其罕见病理类型的恶性肿瘤，大约占全部胃癌的0.17%。其细胞形态和免疫表型与肝细胞癌完全相同。胃肝样腺癌侵袭性高，患者确诊时通常已处于晚期阶段，常见淋巴转移和肝转移。由于其较低的发病率，目前缺乏规范的治疗方案，主要治疗方式包括手术治疗和化疗，但效果不理想。靶向治疗和免疫治疗改变了传统的治疗方法，为肿瘤治疗带来了新的途径。因此我们报告1例胃肝样腺癌伴肝转移晚期患者使用阿帕替尼联合PD-L1抑制剂治疗的病例并回顾了现有的文献和相关知识，为这种罕见类型疾病提供新的治疗思路。
Gastric hepatoid adenocarcinoma is an extremely rare pathological type of malignant tumor, ac-counting for about 0.17% of all gastric cancer. Its morphology and immunophenotype are exactly similar to hepatocellular carcinoma. Gastric hepatoid adenocarcinoma is highly aggressive, and usually at an advanced stage when diagnosed with lymphatic metastases and liver metastases. Due to its low incidence, there is a lack of standardized treatment options. At present, the main treat-ment methods include surgery and chemotherapy, but the treatment effect is not satisfactory. Tar-geted therapy and immunotherapy have changed the traditional treatment methods and brought new approaches for the tumor treatment. Therefore, we reported a case of advanced gastric hepatoid adenocarcinoma patient with liver metastases receiving apatinib combined with PD-L1 inhibitors, and reviewed the current literature and relevant knowledge to provide original treat-ment ideas for this rare malignant tumor.
| [1] | Soreide, J.A. (2019) Therapeutic Approaches to Gastric Hepatoid Adenocarcinoma: Current Perspectives. Therapeutics and Clinical Risk Management, 15, 1469-1477. https://doi.org/10.2147/TCRM.S204303 |
| [2] | Lin, C.Y., Yeh, H.C., Hsu, C.M., et al. (2015) Clinicopathologial Features of Gastric Hepatoid Adenocarcinoma. Biomedical Journal, 38, 65-69. https://doi.org/10.4103/2319-4170.126860 |
| [3] | Baek, S.K., Han, S.W., Oh, D.Y., et al. (2011) Clinicopath-ologic Characteristics and Treatment Outcomes of Hepatoid Adenocarcinoma of the Stomach, a Rare but Unique Subtype of Gastric Cancer. BMC Gastroenterology, 11, Article No. 56. https://doi.org/10.1186/1471-230X-11-56 |
| [4] | Nishida, K., Toji, T., Taniguchi, K., et al. (2023) High-Grade En-dometrial Carcinoma with a Hepatoid Carcinoma-Like Component. International Journal of Gynecological Pathology, 42, 63-67.
https://doi.org/10.1097/PGP.0000000000000852 |
| [5] | Li, M., Fan, Y. and Lu, H. (2021) Hepatoid Adenocarcino-ma of the Lung. Technology in Cancer Research & Treatment, 20. https://doi.org/10.1177/15330338211057983 |
| [6] | Yang, C., Sun, L., Lai, J.Z., et al. (2019) Primary Hepatoid Car-cinoma of the Pancreas: A Clinicopathological Study of 3 Cases with Review of Additional 31 Cases in the Literature. International Journal of Surgical Pathology, 27, 28-42.
https://doi.org/10.1177/1066896918783468 |
| [7] | Acosta, A.M. and Pins, M.R. (2019) Hepatoid Carcinoma of the Ovary: Clinical, Histopathologic, and Immunophenotypic Features. Archives of Pathology & Laboratory Medicine, 143, 883-889.
https://doi.org/10.5858/arpa.2017-0485-RS |
| [8] | Devi, N.R., Sathyalakshmi, R., Devi, J., et al. (2015) Hepatoid Adenocarcinoma of the Gall Bladder—A Rare Variant. Journal of Clinical and Diagnostic Research, 9, ED09-ED10. https://doi.org/10.7860/JCDR/2015/10799.6324 |
| [9] | Nagai, Y., Kato, T., Harano, M., et al. (2014) A Case of AFP-Producing Esophagogastric Junction Cancer with Liver Metastases with a Good Response to Chemotherapy. Gan to Kagaku Ryoho, 41, 2349-2351. |
| [10] | Wang, N., Kong, R., Han, W., et al. (2021) Aberrant Beta-Catenin Activity in Hepatoid Adenocarcinoma of the Stomach. Current Molecular Medicine, 21, 655-664. https://doi.org/10.2174/0929867327666200522215607 |
| [11] | Su, J.S., Chen, Y.T., Wang, R.C., et al. (2013) Clini-copathological Characteristics in the Differential Diagnosis of Hepatoid Adenocarcinoma: A Literature Review. World Journal of Gastroenterology, 19, 321-327.
https://doi.org/10.3748/wjg.v19.i3.321 |
| [12] | Inagawa, S., Shimazaki, J., Hori, M., et al. (2001) Hepatoid Adenocar-cinoma of the Stomach. Gastric Cancer, 4, 43-52.
https://doi.org/10.1007/s101200100016 |
| [13] | Xia, R., Zhou, Y., Wang, Y., et al. (2021) Hepatoid Adenocarcinoma of the Stomach: Current Perspectives and New Developments. Frontiers in Oncology, 11, Article ID: 633916. https://doi.org/10.3389/fonc.2021.633916 |
| [14] | Mckusick, V.A. and Amberger, J.S. (1994) The Morbid Anatomy of the Human Genome: Chromosomal Location of Mutations Causing Disease (Update 1 December 1993). Journal of Medical Genetics, 31, 265-279.
https://doi.org/10.1136/jmg.31.4.265 |
| [15] | Yoshizawa, J., Ishizone, S., Ikeyama, M., et al. (2017) Gastric Hepatoid Adenocarcinoma Resulting in a Spontaneous Gastric Perforation: A Case Report and Review of the Literature. BMC Cancer, 17, Article No. 368.
https://doi.org/10.1186/s12885-017-3357-7 |
| [16] | Simmet, V., Noblecourt, M., Lizee, T., et al. (2018) Chemothera-py of Metastatic Hepatoid Adenocarcinoma: Literature Review and Two Case Reports with Cisplatin Etoposide. Oncolo-gy Letters, 15, 48-54.
https://doi.org/10.3892/ol.2017.7263 |
| [17] | Scott, L.J. (2018) Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers. Drugs, 78, 747-758.
https://doi.org/10.1007/s40265-018-0903-9 |
| [18] | Pardoll, D.M. (2012) The Blockade of Immune Checkpoints in Cancer Immunotherapy. Nature Reviews Cancer, 12, 252-264. https://doi.org/10.1038/nrc3239 |
| [19] | Ganesh, K., Stadler, Z.K., Cercek, A., et al. (2019) Immunotherapy in Colorectal Cancer: Rationale, Challenges and Potential. Nature Reviews Gastroenterology & Hepatology, 16, 361-375. https://doi.org/10.1038/s41575-019-0126-x |
| [20] | Arakawa, Y., Tamura, M., Aiba, K., et al. (2017) Significant Response to Ramucirumab Monotherapy in Chemotherapy-Resistant Recurrent Alpha-Fetoprotein-Producing Gastric Cancer: A Case Report. Oncology Letters, 14, 3039-3042.
https://doi.org/10.3892/ol.2017.6514 |
| [21] | Zou, M., Li, Y., Dai, Y., et al. (2019) AFP-Producing Hepatoid Adeno-carcinoma (HAC) of Peritoneum and Omentum: A Case Report and Literature Review. OncoTargets and Therapy, 12, 7649-7654.
https://doi.org/10.2147/OTT.S216501 |
| [22] | Wang, Y., Sun, L., Li, Z., et al. (2019) Hepatoid Adenocarcinoma of the Stomach: A Unique Subgroup with Distinct Clinicopathological and Molecular Features. Gastric Cancer, 22, 1183-1192.
https://doi.org/10.1007/s10120-019-00965-5 |
